论文部分内容阅读
目的:通过新辅助化疗提高三阴性乳腺癌(TNBC)手术切除的近期和远期疗效并比较两种不同方案新辅助化疗的治疗效果。方法:128例局部晚期TNBC患者分为两组,A组采取ET(吡柔比星联合多西他赛)方案,B组采取GP(顺铂联合吉西他滨)方案进行新辅助化疗,观察化疗后病理反应及其与远期生存的关系。结果:ET组有效率为88.7%,GP组为82.0%。两组5年总生存率和5年无病生存率(DFS)分别为75.4%、71.4%和85.3%、58.9%。结论:TNBC对紫杉联合蒽环类(ET组)较顺铂联合吉西他滨的(GP组)新辅助化疗更敏感,更易获cCR、pCR。
OBJECTIVE: To improve the short-term and long-term efficacy of neoadjuvant chemotherapy in the surgical resection of triple-negative breast cancer (TNBC) and to compare the effects of neoadjuvant chemotherapy with two different regimens. Methods: 128 patients with locally advanced TNBC were divided into two groups: group A received ET (pirarubicin plus docetaxel); group B received neoadjuvant chemotherapy with GP (cisplatin plus gemcitabine) regimen; postoperative chemotherapy Response and its relationship with long-term survival. Results: The effective rate was 88.7% in ET group and 82.0% in GP group. The 5-year overall survival and 5-year disease-free survival (DFS) were 75.4%, 71.4%, 85.3% and 58.9%, respectively. CONCLUSION: TNBC is more sensitive to neoadjuvant chemotherapy with taxane combined anthracycline (ET) than cisplatin combined with gemcitabine (GP), and is more likely to be cCR, pCR.